Experts Video Reports: Precision Medicine track

Learn about key results illustrated by slides from the sessions!

The Precision Medicine track 2019 is supported with an unrestricted grant from Bayer Healthcare . The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

ESMO Expert video report on detection of gene fusions in oncology

Frederique Penault-Llorca explains that gene fusions are rare but present in a high number of cancers and several of them are already targetable. From an array of gene fusions, she details on NTRK family which requires a specific approach regarding detection because of an agnostic biomarker’s nature. She details about techniques for detection of alterations and the recommendations for testing algorithm to apply.

ESMO Expert video report on epidemiology and distribution of NTRK gene fusions in human tumours

Ulrik Lassen provides an overview of the frequency and distribution of NTRK gene fusions in rare and common human cancers, in particular very high occurrences in some rare cancers where their detection is also a part of diagnostic work-up and a low rate in some frequent cancers. Recent approvals of effective drugs might lead to the change in molecular testing mode: switching from time consuming and costly individual gene fusions detection to NGS.

ESMO Expert Video Report: Targeting NTRK gene fusions across cancers

TRK fusions are highly actionable driver alterations. A. Drilon gives an overview of their frequency in different cancer types, and explains how to screen for these alterations with next generation sequencing, immunohistochemistry or FISH. He details the targeted therapies which have shown very high and durable response rates, as well as the mechanisms of resistance and how to tackle it.

ELCC 2019: Expert Video Report: Different perspectives on Tumour Mutational Burden

Reporting from ELCC 2019 in Geneva, M. Pérol explains the Tumour Mutational Burden from the biomarker’s perspective, details recent assessment methods and how the test results may be useful in Non-Small Cell Lung Cancer patients to select first-line treatment.

Session: State of art of TMB testing

ELCC 2019 Highlight: Targeting fusions in Lung Cancer

Reporting from ELCC 2019 in Geneva, J. Wolf comments on the importance of searching for actionable genetic aberrations in NSCLC. He elaborates upon different gene fusions and in particular TRK fusion in terms of identifying patients who could benefit from effective new targeted therapies.

AACR 2019: Expert Video Report on Liquid Biopsy

Reporting from AACR 2019 in Atlanta, F-C. Bidard comments on clinical utility of CTCs and ctDNA as biomarkers based on the results from two studies in breast and prostate cancer.


Track 2018: Expert Video reports from ESMO Congress and ASCO conference

















Highlights in metastatic colorectal cancer CheckMate 142

Prof Heinz-Josef Lenz reports on key results from ESMO 2018 Congress: LBA 18_PR: Durable Clinical Benefit With Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer.

Highlights in advanced ovarian cancer - SOLO1

Dr. Nicoletta Colombo reports on key results from ESMO 2018 Congress: LBA7_PR: Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation: Phase III SOLO1 trial.

Highlights in HR-positive, HER2-negative advanced breast cancer PALOMA-3

Dr. Massimo Cristofanilli reports on key results from ESMO 2018 Congress: LBA2_PR: Overall survival with palbociclib plus fulvestrant in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analyses from PALOMA-3.

Highlights in Metastatic NSCLC, ASCEND-3

Dr. Enriqueta Felip reports on key results from ESMO 2018 Congress: LBA57: Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)

Highlights in drugging PIK3CA-mutated tumours, the SANDPIPER and MATCH trials

Dejan Juric reports on the results presented at ASCO 2018 from studies that tested addition of selective PIK3CA inhibitor in selected populations of patients, but the treatment caused considerable side effects.

Tumour mutation burden, a novel biomarker

Reporting from ASCO 2018, Mark Ladanyi explains that tumour mutation burden (TMB) is emerging after PD-L1 as a major biomarker of response to immune checkpoints inhibitors. We need to learn more about patients status regarding TMB and PD-L1 across tumour types and two studies addressing this question were presented at this meeting.


More ESMO videos on Precision Medicine from the ESMO Channel

View the full playlist on the ESMO Channel

ESMO thanks the sponsor for supporting this track in 2019: